You'll see manufacturers market more metabolites and isomers of existing drugs to replace drugs with expiring patents

February 2007

You'll see manufacturers market more metabolites and isomers of existing drugs to replace drugs with expiring patents.

The pitch is often that the active isomer or metabolite will give better efficacy...or fewer side effects.

Some new products live up to these expectations...some don't.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

You'll see manufacturers market more metabolites and isomers of existing drugs to replace drugs with expiring patents
Osteoporosis whether proton pump inhibitors (omeprazole, etc) increase the risk for fractures
Osteoporosis Women are hearing that they can take a break from their oral bisphosphonate (Fosamax, etc)
Interactions misconceptions about grapefruit juice interactions
Men's Health anticholinergics (Detrol, Ditropan, etc) for urinary symptoms in men with benign prostatic hyperplasia
Cardiology Patients are asking if their meds for Parkinson's or restless legs will cause heart trouble
Cardiology BOTH Plavix and aspirin for at least 12 months after getting a drug-eluting coronary stent
Substance Use Disorder dextromethorphan abuse in teens
Vaccines More patients will be getting human papillomavirus, pertussis, and herpes zoster vaccines
Dermatology New evidence is helping to clear up what works for rosacea
Hormone Therapy controversy about bioidentical hormones
Infectious Diseases Ketek will eventually be severely curtailed or go off the market
Practice the significant new drugs approved in 2006